Rising Pharma Holdings, Inc. Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Rising Pharma Holdings, Inc. Pharmaceutical Import Records from India — 18 Products, $87.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Rising Pharma Holdings, Inc. — Pharmaceutical Importer Profile (2026) | 18 Products, $87.0M Trade | TransData Nexus

Rising Pharma Holdings, Inc.

Pharmaceutical Importer · United States · CNS & Psychiatric Focus · $87.0M Total Trade · DGFT Verified

Rising Pharma Holdings, Inc. is a pharmaceutical importer based in United States with a total trade value of $87.0M across 18 products in 11 therapeutic categories. Based on 4,132 verified import shipments from Indian Customs (DGFT) records, Rising Pharma Holdings, Inc. is the #1 buyer in 1 product including Pioglitazone. Rising Pharma Holdings, Inc. sources from 13 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 48.4% of imports.

Rising Pharma Holdings, Inc. — Import Portfolio & Supplier Network

Rising Pharma Holdings, Inc. import network — 18 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Rising Pharma Holdings, Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$73.0M	2,855	48.4%
Graviti Pharmaceuticals Private Limited	$47.1M	3,260	31.3%
J B Chemicals And Pharmaceuticals Limited

What Formulations Does Rising Pharma Holdings, Inc. Import?

Formulation	Value	Ships
Duloxetine delayed -release capsules	$6.1M	132
Ondansetron orally disintegrating	$3.4M	91
Divalproex sodium delayed-release	$1.8M	53
Duloxetine delayed-release capsules 20MG	$1.6M	38
Glipizide extended-release tablets 10 MG	$1.5M	33
Df sodium dr tabs 75 MG 60 pk usa	$1.5M	39
Cetrizine tablets 10MG (cetirizine hcl	$1.3M	28
Ondansetron tablets 8MG (89664x30's)	$1.2M	24
Timolol maleate sterile ophthalmic	$1.2M	39
Carbamazepine extended-release tablets	$1.0M	25
Df sodium dr tabs 75 MG 500's pk usa	$895.0K	23
Ondansetron orally disintegrating tablets 4MG (115200x30's)	$884.1K	26
Diclofenac dr tabs 50 MG 100 pk usa	$869.1K	23
Glipizide extended-release tablets 2.5	$845.1K	19
Ofloxacin ophthalmic solution USP 0.3%	$836.2K	17

Rising Pharma Holdings, Inc. imports 4,143 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 18 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gabapentin	CNS & Psychiatric	$21.2M	705	1.3%	10
2	Furosemide	Diuretics	$14.0M	1,711	8.9%	2
3	Ondansetron	Gastrointestinal	$13.2M	385	4.2%	4
4	Pioglitazone	Diabetes & Endocrine	$8.3M	255	7.6%	1
5	Escitalopram	CNS & Psychiatric	$4.7M	230	1.6%	7
6	Fluconazole	Antifungals	$4.4M	174	1.9%	5
7	Metoprolol	Cardiovascular	$3.1M	90	0.4%	19
8	Citalopram	CNS & Psychiatric	$3.1M	174	1.2%	13
9	Ofloxacin	Advanced Antibiotics	$3.0M	61	1.0%	13
10	Loratadine	Antihistamines & Allergy	$2.5M	54	0.9%	9
11	Cetirizine	Antihistamines & Allergy	$2.5M	50	1.4%	7
12	Atenolol	Cardiovascular	$2.5M	77	3.5%	6
13	Repaglinide	Advanced Diabetes Medications	$1.3M	55	6.7%	3
14	Ramipril	Cardiovascular	$993.6K	63	1.1%	18
15	Clarithromycin	Antibiotics	$950.0K	19	0.3%	10
16	Lansoprazole	Gastrointestinal	$750.0K	15	0.3%	9
17	Hydrocortisone	Corticosteroids	$250.0K	5	0.4%	5
18	Tinidazole	Advanced Antibiotics	$197.3K	9	1.1%	11

Rising Pharma Holdings, Inc. imports 18 pharmaceutical products across 11 categories into United States totaling $87.0M. The company is the #1 buyer for 1 product: Pioglitazone.

Rising Pharma Holdings, Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Rising Pharma Holdings, Inc., operating under the trade name Rising Pharmaceuticals, is a privately held pharmaceutical company headquartered in East Brunswick, New Jersey. Established in 1990, the company specializes in the marketing and distribution of generic prescription and over-the-counter (OTC) pharmaceutical products across the United States. Their diverse portfolio encompasses a wide range of therapeutic areas and multiple dosage forms, including tablets, capsules, syrups, and injections. Rising Pharmaceuticals is committed to delivering high-quality, accessible medications, ensuring that every product undergoes rigorous quality assurance protocols to meet regulatory standards.

In April 2019, Rising Pharma Holdings, Inc. acquired the assets of Rising Pharmaceuticals, Inc., a company based in Saddle Brook, New Jersey, which had filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in February 2019. This acquisition allowed Rising Pharma Holdings to expand its product offerings and strengthen its position in the U.S. pharmaceutical market. The company's leadership team comprises industry experts with extensive experience in pharmaceutical development, marketing, and distribution, driving innovation and ensuring the highest standards of care for patients.

2Distribution Network

Rising Pharmaceuticals operates a comprehensive distribution network across the United States, ensuring the efficient delivery of its pharmaceutical products to various stakeholders, including wholesalers, chain drug stores, distributors, and mass merchandisers. The company's logistics capabilities are designed to maintain a reliable supply chain, facilitating timely and secure delivery of products nationwide. While specific warehouse locations are not publicly disclosed, Rising Pharmaceuticals emphasizes its commitment to quality and customer service, indicating a well-established infrastructure to support its distribution operations.

3Industry Role

Rising Pharmaceuticals plays a significant role in the U.S. pharmaceutical supply chain as a pharmaceutical importer and distributor. By sourcing generic prescription and OTC products from various manufacturers, including those in India, the company ensures a steady supply of affordable medications to the U.S. market. Their operations bridge the gap between international manufacturers and domestic consumers, contributing to the accessibility and affordability of healthcare in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Rising Pharma Holdings, Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Rising Pharmaceuticals demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $87.0 million USD from India, encompassing 4,132 shipments across 18 products in 11 therapeutic categories. The top five products imported include Gabapentin ($21.2 million), Furosemide ($14.0 million), Ondansetron ($13.2 million), Pioglitazone ($8.3 million), and Escitalopram ($4.7 million), collectively accounting for 70.5% of the total import value. This concentration indicates a strategic focus on specific high-demand products, potentially leveraging favorable pricing and manufacturing capabilities in India. However, such dependency on a limited number of suppliers and products may expose Rising Pharmaceuticals to risks related to supply chain disruptions, regulatory changes, or market fluctuations affecting these key products.

2Supply Chain Resilience

Rising Pharmaceuticals' supply chain resilience is influenced by its sourcing strategy, which heavily relies on imports from India. The company's top suppliers include AUROBINDO PHARMA LIMITED, GRAVITI PHARMACEUTICALS PRIVATE LIMITED, and J B CHEMICALS AND PHARMACEUTICALS LIMITED, collectively accounting for a substantial portion of the import value. While these partnerships may offer cost advantages and access to a diverse range of products, the concentration of suppliers poses potential risks. Factors such as geopolitical tensions, regulatory changes, or disruptions in manufacturing capabilities in India could impact the stability of the supply chain. To enhance resilience, Rising Pharmaceuticals may consider diversifying its supplier base, establishing backup suppliers, and ensuring compliance with international quality standards to mitigate potential disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drug applications, including Abbreviated New Drug Applications (ANDAs) for generic drugs. The Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) are key legislative frameworks governing the approval and marketing of generic drugs in the U.S. These regulations ensure that imported pharmaceutical products meet safety, efficacy, and quality standards before reaching the U.S. market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All imported drugs must be approved by the FDA, which involves submitting an ANDA for generic drugs. Manufacturers must adhere to Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal mutual recognition agreement with the European Union, it does accept GMP certifications from countries with which it has established agreements, provided they meet FDA standards. Wholesale distributors like Rising Pharmaceuticals must obtain appropriate licenses to operate, ensuring compliance with federal and state regulations governing the distribution of pharmaceutical products.

Rising Pharma Holdings, Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Rising Pharmaceuticals' product strategy focuses on high-demand therapeutic areas, including Central Nervous System (CNS) & Psychiatric disorders, Diuretics, and Gastrointestinal conditions. The company's top five imported products—Gabapentin, Furosemide, Ondansetron, Pioglitazone, and Escitalopram—align with these therapeutic categories, indicating a strategic emphasis on addressing prevalent health issues. Market demand for these products is driven by the widespread prevalence of conditions such as epilepsy, hypertension, heart failure, nausea, diabetes, and depression, necessitating accessible and effective treatment options.

2Sourcing Profile

Rising Pharmaceuticals' sourcing strategy centers on generic drugs, with a preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs). This approach allows the company to offer a diverse product portfolio without the complexities associated with API sourcing and manufacturing. India's well-established pharmaceutical industry, characterized by a large number of manufacturers and a broad range of products, makes it a strategic sourcing partner for Rising Pharmaceuticals.

3Market Positioning

Seller's Guide — How to Become a Supplier to Rising Pharma Holdings, Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Rising Pharmaceuticals' sourcing network. The company's significant import volume from India and its focus on high-demand therapeutic areas indicate a potential for expanding supplier relationships. Gaps in Rising Pharmaceuticals' current sourcing may include a need for additional suppliers in specific product categories or for products that meet evolving regulatory standards.

2Requirements & Qualifications

Indian exporters seeking to supply Rising Pharmaceuticals and the U.S. market must ensure compliance with FDA regulations, including obtaining ANDA approvals for generic drugs. Manufacturers must adhere to GMP standards recognized by the FDA, and products must meet labeling and serialization requirements. Establishing a reliable supply chain and demonstrating a commitment to quality assurance are essential for gaining entry into

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Rising Pharma Holdings, Inc.

What products does Rising Pharma Holdings, Inc. import from India?

Rising Pharma Holdings, Inc. imports 18 pharmaceutical products across 11 categories. Top imports: Gabapentin ($21.2M), Furosemide ($14.0M), Ondansetron ($13.2M), Pioglitazone ($8.3M), Escitalopram ($4.7M).

Who supplies pharmaceuticals to Rising Pharma Holdings, Inc. from India?

Rising Pharma Holdings, Inc. sources from 13 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (48.4% of imports, $73.0M).

What is Rising Pharma Holdings, Inc.'s total pharmaceutical import value?

Rising Pharma Holdings, Inc.'s total pharmaceutical import value from India is $87.0M, based on 4,132 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Rising Pharma Holdings, Inc. focus on?

Rising Pharma Holdings, Inc. imports across 11 categories. The largest: CNS & Psychiatric (33.4%), Diuretics (16.1%), Gastrointestinal (16.0%).

Get Full Rising Pharma Holdings, Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.